Victoza (liraglutide), the first GLP-1 for type 2 diabetes to lose exclusivity in June 2024, may not generate significant savings due to its once-daily dosing and limited market share
Similar to alcohol, tobacco smoking is another leading cause of premature death
Morton also emphasizes that weight regain is not a personal failure
This variability restricted the possibility of conducting a meta-analysis and emphasized the need for standardized protocols in future research
Related Stories Scientists discover 70 existing drugs that block deadly hantavirus infections Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations Why new Alzheimers drugs are dividing regulators worldwide Options include once-weekly injectables, daily agents, combination therapies with insulin, and newer oral formulations that some patients may prefer, although tolerability and discontinuation remain considerations
What matters most is that the prescribing clinician has experience managing obesity as a chronic disease and can follow you over time
